{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:25:56Z","timestamp":1793827556033,"version":"4.6.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82304622"],"award-info":[{"award-number":["82304622"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04380-5","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:44Z","timestamp":1776257684000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2024"],"prefix":"10.1007","volume":"75","author":[{"given":"Jingyi","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"4380_CR1","doi-asserted-by":"crossref","unstructured":"Hsiehchen D, Hsieh A, Samstein RM et al. (2020) DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden. Cell Rep Med 1(3)","DOI":"10.1016\/j.xcrm.2020.100034"},{"issue":"11","key":"4380_CR2","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/1346-8138.14637","volume":"45","author":"Y Nakamura","year":"2018","unstructured":"Nakamura Y, Fujisawa Y, Tanaka R et al (2018) Use of immune checkpoint inhibitors prolonged overall survival in a Japanese population of advanced malignant melanoma patients: retrospective single institutional study. J Dermatol 45(11):1337\u20131339","journal-title":"J Dermatol"},{"issue":"suppl_4","key":"4380_CR3","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Annals Oncol: Off J Eur Soc Med Oncol 28(suppl_4):iv119\u2013iv142","journal-title":"Annals Oncol: Off J Eur Soc Med Oncol"},{"issue":"12","key":"4380_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728","journal-title":"JAMA Oncol"},{"issue":"1","key":"4380_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.17305\/bb.2024.10833","volume":"25","author":"H Su","year":"2024","unstructured":"Su H, Yu C, Sun G et al (2024) Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP. Biomol Biomed 25(1):29\u201341","journal-title":"Biomol Biomed"},{"key":"4380_CR6","doi-asserted-by":"publisher","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","volume":"15","author":"B Zhao","year":"2024","unstructured":"Zhao B, Fu Y, Cui S et al (2024) A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system. Front Pharmacol 15:1333662","journal-title":"Front Pharmacol"},{"issue":"4","key":"4380_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","volume":"19","author":"H Yang","year":"2023","unstructured":"Yang H, Wan Z, Chen M et al (2023) A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database. Expert Opin Drug Metab Toxicol 19(4):217\u2013223","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"4380_CR8","first-page":"1193","volume":"30","author":"EA Alghamdi","year":"2022","unstructured":"Alghamdi EA, Aljohani H, Alghamdi W et al (2022) Immune checkpoint inhibitors and potential risk of thromboembolic events: analysis of the WHO global database of individual case safety reports. Saudi Pharm J: SPJ: Off Publ Saudi Pharm Soc 30(8):1193\u20131199","journal-title":"Saudi Pharm J: SPJ: Off Publ Saudi Pharm Soc"},{"key":"4380_CR9","doi-asserted-by":"publisher","first-page":"109243","DOI":"10.1016\/j.thromres.2024.109243","volume":"246","author":"J Lin","year":"2025","unstructured":"Lin J, Li W, Zhang X et al (2025) Thromboembolic events associated with immune checkpoint inhibitors in cancer patients: a Bayesian network meta-analysis. Thromb Res 246:109243","journal-title":"Thromb Res"},{"issue":"4","key":"4380_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hon.2743","volume":"38","author":"X Ye","year":"2020","unstructured":"Ye X, Hu F, Zhai Y et al (2020) Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019. Hematol Oncol 38(4):565\u2013575","journal-title":"Hematol Oncol"},{"key":"4380_CR11","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y et al (2022) Post-marketing safety concerns with Secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol 13:862508","journal-title":"Front Pharmacol"},{"key":"4380_CR12","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L et al (2020) Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol 84:106601","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"4380_CR13","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.esmoop.2021.100315","volume":"6","author":"NE Omar","year":"2021","unstructured":"Omar NE, Fahmy Soliman AI, Eshra M et al (2021) Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA adverse event reporting system (FAERS). ESMO Open 6(6):100315","journal-title":"ESMO Open"},{"key":"4380_CR14","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","volume":"14","author":"Z Cui","year":"2023","unstructured":"Cui Z, Cheng F, Wang L et al (2023) A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say? Front Pharmacol 14:1259908","journal-title":"Front Pharmacol"},{"issue":"6","key":"4380_CR15","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","volume":"19","author":"F Conforti","year":"2018","unstructured":"Conforti F, Pala L, Bagnardi V et al (2018) Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol 19(6):737\u2013746","journal-title":"Lancet Oncol"},{"issue":"12","key":"4380_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19(12):1579\u20131589","journal-title":"Lancet Oncol"},{"key":"4380_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K et al (2018) Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 103:7\u201316","journal-title":"Eur J Cancer"},{"key":"4380_CR18","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.3389\/fimmu.2020.01354","volume":"11","author":"NE Omar","year":"2020","unstructured":"Omar NE, El-Fass KA, Abushouk AI et al (2020) Diagnosis and management of hematological adverse events induced by immune checkpoint inhibitors: a systematic review. Front Immunol 11:1354","journal-title":"Front Immunol"},{"issue":"1","key":"4380_CR19","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57","journal-title":"Lancet Haematol"},{"issue":"16","key":"4380_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R et al (2019) Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546","journal-title":"N Engl J Med"},{"issue":"3","key":"4380_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C et al (2019) Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract 25(3):551\u2013557","journal-title":"J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract"},{"key":"4380_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/JBM.S46255","volume":"5","author":"MR George","year":"2014","unstructured":"George MR (2014) Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med 5:69\u201386","journal-title":"J Blood Med"},{"key":"4380_CR23","doi-asserted-by":"publisher","first-page":"765608","DOI":"10.3389\/fonc.2021.765608","volume":"11","author":"A Zaremba","year":"2021","unstructured":"Zaremba A, Kramer R, DE Temple V et al (2021) Grade 4 neutropenia secondary to immune checkpoint inhibition-a descriptive observational retrospective multicenter analysis. Front Oncol 11:765608","journal-title":"Front Oncol"},{"issue":"4","key":"4380_CR24","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et al (2016) Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 27(4):559\u2013574","journal-title":"Ann Oncol"},{"issue":"14","key":"4380_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R et al (2017) Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"key":"4380_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390","journal-title":"Eur J Cancer"},{"issue":"6","key":"4380_CR27","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M et al (2020) Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 6(6):865\u2013871","journal-title":"JAMA Oncol"},{"key":"4380_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejca.2021.01.013","volume":"147","author":"R Kramer","year":"2021","unstructured":"Kramer R, Zaremba A, Moreira A et al (2021) Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer 147:170\u2013181","journal-title":"Eur J Cancer"},{"issue":"8","key":"4380_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1056\/NEJM199908193410807","volume":"341","author":"M Levi","year":"1999","unstructured":"Levi M, TEN Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341(8):586\u2013592","journal-title":"N Engl J Med"},{"key":"4380_CR30","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.12688\/f1000research.12498.1","volume":"6","author":"Y Alhamdi","year":"2017","unstructured":"Alhamdi Y, Toh CH (2017) Recent advances in pathophysiology of disseminated intravascular coagulation: the role of circulating histones and neutrophil extracellular traps. F1000Res 6:2143","journal-title":"F1000Res"},{"issue":"10","key":"4380_CR31","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907","journal-title":"Blood"},{"issue":"Suppl 1","key":"4380_CR32","first-page":"S69","volume":"131","author":"A Falanga","year":"2013","unstructured":"Falanga A, Russo L, Verzeroli C (2013) Mechanisms of thrombosis in cancer. Thromb Res 131(Suppl 1):S69\u2013S62","journal-title":"Thromb Res"},{"issue":"4","key":"4380_CR33","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","volume":"18","author":"VK Morris","year":"2017","unstructured":"Morris VK, Salem ME, Nimeiri H et al (2017) Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446\u2013453","journal-title":"Lancet Oncol"},{"issue":"3","key":"4380_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, van Tine BA et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416\u2013426","journal-title":"Lancet Oncol"},{"issue":"5","key":"4380_CR35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajh.25448","volume":"94","author":"RK Leaf","year":"2019","unstructured":"Leaf RK, Ferreri C, Rangachari D et al (2019) Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol 94(5):563\u2013574","journal-title":"Am J Hematol"},{"issue":"2","key":"4380_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13187","volume":"102","author":"GE Tanios","year":"2019","unstructured":"Tanios GE, Doley PB, Munker R (2019) Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol 102(2):157\u2013162","journal-title":"Eur J Haematol"},{"issue":"1","key":"4380_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-018-0365-3","volume":"6","author":"M Sadaat","year":"2018","unstructured":"Sadaat M, Jang S (2018) Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report. J Immunother Cancer 6(1):49","journal-title":"J Immunother Cancer"},{"key":"4380_CR38","first-page":"100871","volume":"28","author":"H Mori","year":"2019","unstructured":"Mori H, Sakai C, Iwai M et al (2019) Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer. Respir Med Case Rep 28:100871","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"4380_CR39","first-page":"73","volume":"17","author":"D Kratzsch","year":"2019","unstructured":"Kratzsch D, Simon JC, P\u00f6nitzsch I et al (2019) Lethal thrombocytopenia in a patient treated with avelumab for metastatic Merkel cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol\u202f: JDDG 17(1):73\u20135","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft = J German Soc Dermatol : JDDG"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04380-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04380-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04380-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:54:47Z","timestamp":1776257687000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04380-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4380"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04380-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"147"}}